{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:23:17Z","timestamp":1789539797314,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-16384-9","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T06:01:39Z","timestamp":1756188099000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A real-world safety signal detection study of ondansetron based on FAERS reports from 2014 to 2024"],"prefix":"10.1038","volume":"15","author":[{"given":"Fan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaona","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"issue":"11","key":"16384_CR1","doi-asserted-by":"publisher","first-page":"8855","DOI":"10.1007\/s00520-022-07287-w","volume":"30","author":"P Patel","year":"2022","unstructured":"Patel, P. et al. Interventions for the prevention of acute phase chemotherapy-induced nausea and vomiting in adult and pediatric patients: A systematic review and meta-analysis. Support. Care Cancer 30(11), 8855\u20138869. https:\/\/doi.org\/10.1007\/s00520-022-07287-w (2022).","journal-title":"Support. Care Cancer"},{"issue":"6","key":"16384_CR2","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2165\/00003495-199345060-00006","volume":"45","author":"A Markham","year":"1993","unstructured":"Markham, A. & Sorkin, E. M. Ondansetron\u2013an update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting. Drugs 45(6), 931\u2013952. https:\/\/doi.org\/10.2165\/00003495-199345060-00006 (1993).","journal-title":"Drugs"},{"key":"16384_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-020-0713-6","author":"ID Florez","year":"2020","unstructured":"Florez, I. D., Ni\u00f1o-Serna, L. F. & Beltr\u00e1n-Arroyave, C. P. Acute infectious diarrhea and gastroenteritis in children. Curr. Infect. Dis. Rep. https:\/\/doi.org\/10.1007\/s11908-020-0713-6 (2020).","journal-title":"Curr. Infect. Dis. Rep."},{"issue":"10","key":"16384_CR4","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1136\/gutjnl-2013-305989","volume":"63","author":"K Garsed","year":"2014","unstructured":"Garsed, K. et al. A randomised trial of Ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut 63(10), 1617. https:\/\/doi.org\/10.1136\/gutjnl-2013-305989 (2014).","journal-title":"Gut"},{"issue":"2","key":"16384_CR5","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/sla.0000000000005995","volume":"279","author":"SG Popeskou","year":"2024","unstructured":"Popeskou, S. G. et al. Ondansetron for low anterior resection syndrome (LARS) a double-blind, placebo-controlled, cross-over, randomized study. Annals Surg. 279(2), 196\u2013202. https:\/\/doi.org\/10.1097\/sla.0000000000005995 (2024).","journal-title":"Annals Surg."},{"issue":"11","key":"16384_CR6","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1177\/0269881118798608","volume":"32","author":"J Kulkarni","year":"2018","unstructured":"Kulkarni, J., Thomas, N., Hudaib, A.-R., Gavrilidis, E. & Gurvich, C. Ondansetron\u2014a promising adjunctive treatment for persistent schizophrenia. J. Psychopharmacol. 32(11), 1204\u20131211. https:\/\/doi.org\/10.1177\/0269881118798608 (2018).","journal-title":"J. Psychopharmacol."},{"issue":"10","key":"16384_CR7","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1517\/14740338.2014.954546","volume":"13","author":"L Brygger","year":"2014","unstructured":"Brygger, L., Herrstedt, J., Academy of Geriatric Cancer Research. 5-Hydroxytryptamine3 receptor antagonists and cardiac side effects. Exp. Opin. Drug Saf. 13(10), 1407\u20131422. https:\/\/doi.org\/10.1517\/14740338.2014.954546 (2014).","journal-title":"Exp. Opin. Drug Saf."},{"key":"16384_CR8","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2273334","author":"R Barus","year":"2023","unstructured":"Barus, R., Potey, C., Gautier, S. & Wabont, G. Ondansetron induced blindness: A pharmacovigilance database study. Expert Opin. Drug Saf. https:\/\/doi.org\/10.1080\/14740338.2023.2273334 (2023).","journal-title":"Expert Opin. Drug Saf."},{"issue":"12","key":"16384_CR9","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1592\/phco.28.12.1542","volume":"28","author":"MJ Lewandowski","year":"2008","unstructured":"Lewandowski, M. J. & Chapman, S. A. Ondansetron-induced aminotransferase level elevation: Case report and review of the literature. Pharmacotherapy 28(12), 1542\u20131546. https:\/\/doi.org\/10.1592\/phco.28.12.1542 (2008).","journal-title":"Pharmacotherapy"},{"issue":"12","key":"16384_CR10","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1111\/j.1528-1167.2009.02139.x","volume":"50","author":"NN Singh","year":"2009","unstructured":"Singh, N. N., Rai, A., Selhorst, J. B. & Acharya, J. N. Ondansetron and seizures. Epilepsia 50(12), 2663\u20132666. https:\/\/doi.org\/10.1111\/j.1528-1167.2009.02139.x (2009).","journal-title":"Epilepsia"},{"issue":"2","key":"16384_CR11","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1161\/01.CIR.81.2.686","volume":"81","author":"LM Hondeghem","year":"1990","unstructured":"Hondeghem, L. M. & Snyders, D. J. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation 81(2), 686\u2013690. https:\/\/doi.org\/10.1161\/01.CIR.81.2.686 (1990).","journal-title":"Circulation"},{"issue":"10","key":"16384_CR12","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMra032426","volume":"350","author":"DM Roden","year":"2004","unstructured":"Roden, D. M. Drug-induced prolongation of the QT Interval. N. Engl. J. Med. 350(10), 1013\u20131022. https:\/\/doi.org\/10.1056\/NEJMra032426 (2004).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"16384_CR13","doi-asserted-by":"publisher","first-page":"E15","DOI":"10.1097\/aog.0000000000002450","volume":"131","author":"SM Ramin","year":"2018","unstructured":"Ramin, S. M. & Comm Practice, B.-O. Nausea and vomiting of pregnancy. Obstet. Gynecol. 131(1), E15\u2013E30. https:\/\/doi.org\/10.1097\/aog.0000000000002450 (2018).","journal-title":"Obstet. Gynecol."},{"issue":"7","key":"16384_CR14","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/1471-0528.17739","volume":"131","author":"C Nelson-Piercy","year":"2024","unstructured":"Nelson-Piercy, C. et al. The management of nausea and vomiting in pregnancy and hyperemesis Gravidarum (green-top guideline no. 69). Bjog-an Int. J. Obstet. Gynaecol. 131(7), e1\u2013e30. https:\/\/doi.org\/10.1111\/1471-0528.17739 (2024).","journal-title":"Bjog-an Int. J. Obstet. Gynaecol."},{"key":"16384_CR15","unstructured":"<ACOG Practice Bulletin No. 189 Nausea And Vomiting Of Pregnancy.pdf>."},{"key":"16384_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.reprotox.2018.10.010","volume":"83","author":"A Zambelli-Weiner","year":"2019","unstructured":"Zambelli-Weiner, A., Via, C., Yuen, M., Weiner, D. J. & Kirby, R. S. First trimester Ondansetron exposure and risk of structural birth defects. Reprod. Toxicol. 83, 14\u201320. https:\/\/doi.org\/10.1016\/j.reprotox.2018.10.010 (2019).","journal-title":"Reprod. Toxicol."},{"issue":"23","key":"16384_CR17","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1001\/jama.2018.18307","volume":"320","author":"KF Huybrechts","year":"2018","unstructured":"Huybrechts, K. F. et al. Association of maternal first-trimester ondansetron use with cardiac malformations and oral clefts in offspring. Jama-J. Am. Med. Assoc. 320(23), 2429\u20132437. https:\/\/doi.org\/10.1001\/jama.2018.18307 (2018).","journal-title":"Jama-J. Am. Med. Assoc."},{"issue":"4","key":"16384_CR18","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1001\/jama.2019.18587","volume":"323","author":"KF Huybrechts","year":"2020","unstructured":"Huybrechts, K. F. et al. Intravenous ondansetron in pregnancy and risk of congenital malformations. Jama-J. Am. Med. Assoc. 323(4), 372\u2013374. https:\/\/doi.org\/10.1001\/jama.2019.18587 (2020).","journal-title":"Jama-J. Am. Med. Assoc."},{"issue":"10","key":"16384_CR19","doi-asserted-by":"publisher","first-page":"4858","DOI":"10.3390\/ijms26104858","volume":"26","author":"MD Tkachenko","year":"2025","unstructured":"Tkachenko, M. D., Alyoshina, N. M., Nikishina, Y. O., Frolova, V. S. & Nikishin, D. A. Impact of chronic fluoxetine exposure on oocyte development and reproductive outcomes in a mouse model. Int. J. Mol. Sci. 26(10), 4858 (2025).","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"16384_CR20","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1111\/bph.13482","volume":"173","author":"D Utsumi","year":"2016","unstructured":"Utsumi, D., Matsumoto, K., Amagase, K., Horie, S. & Kato, S. 5-HT3 receptors promote colonic inflammation via activation of substance P\/neurokinin-1 receptors in dextran sulphate sodium-induced murine colitis. Br. J. Pharmacol. 173(11), 1835\u20131849. https:\/\/doi.org\/10.1111\/bph.13482 (2016).","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"16384_CR21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1176\/appi.ajp.20240294","volume":"182","author":"ER Stern","year":"2025","unstructured":"Stern, E. R. et al. Randomized controlled trial of the effects of high-dose ondansetron on clinical symptoms and brain connectivity in obsessive-compulsive and tic disorders. Am. J. Psychiatry 182(3), 285\u2013296. https:\/\/doi.org\/10.1176\/appi.ajp.20240294 (2025).","journal-title":"Am. J. Psychiatry"},{"key":"16384_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1372401","author":"D Li","year":"2024","unstructured":"Li, D. et al. Post-marketing risk analysis of bendamustine: A real-world approach based on the FAERS database. Front. Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2024.1372401 (2024).","journal-title":"Front. Pharmacol."},{"issue":"7","key":"16384_CR23","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda, T., Tamon, A., Kadoyama, K. & Okuno, Y. Data mining of the public version of the FDA adverse event reporting system. Int. J. Med. Sci. 10(7), 796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048 (2013).","journal-title":"Int. J. Med. Sci."},{"key":"16384_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1382441","author":"JQ Wu","year":"2024","unstructured":"Wu, J. Q., Pan, H., Shen, L. & Zhao, M. Y. Assessing the safety of bedaquiline: Insight from adverse event reporting system analysis. Front. Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2024.1382441 (2024).","journal-title":"Front. Pharmacol."},{"key":"16384_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1388138","author":"NS Tian","year":"2024","unstructured":"Tian, N. S. et al. Safety assessment of tranexamic acid: Real-world adverse event analysis from the FAERS database. Front. Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2024.1388138 (2024).","journal-title":"Front. Pharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16384-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16384-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16384-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:38:37Z","timestamp":1757464717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16384-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["16384"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-16384-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"assertion":[{"value":"15 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval and informed consent were not required for this study, as the FAERS database is publicly accessible and all patient records are anonymized and de-identified.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"31339"}}